Adult psoriasis represents an increasingly lucrative market for biologics to treat the moderate to severe population, for whom conventional systemic and topical treatments alone are not sufficient. Of the targeted therapies, Novartis’s interleukin (IL)-17 inhibitor, Cosentyx; Janssen’s IL-12/23 inhibitor, Stelara; and AbbVie’s TNF-α inhibitor, Humira, dominate the landscape. The only oral, targeted therapy, Amgen’s Otezla, also holds a substantial patient share. However, the patient shares of established targeted agents are increasingly being challenged by the arrival of later-to-market biologics—such as Janssen’s Tremfya, AbbVie's Skyrizi, and Eli Lilly’s Taltz—leading to interesting dynamics in the psoriasis market.
Markets covered: United States
Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis, UCB
Key drugs: Cimzia, Cosentyx, Duobrii, Enbrel, Humira, Otezla, Remicade, Skyrizi, Stelara, Taltz, Tremfya
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketer scan accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.